Schulz Marcus's Form 4/A amendment
AmendedBiolife Solutions Inc (BLFS) · filed May 16, 2023
- Accession no.
- 0001437749-23-014862
- Filed
- May 16, 2023
- Trade date
- Mar 31-Apr 6, 2023
- Filing delay
- 46 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Apr 10, 2023
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $15.4K. It was filed 46 days after the trade.
This amendment replaces 0001437749-23-009875 (filed Apr 10, 2023).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schulz MarcusCIK 0001812702 | Officer (Chief Revenue Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2023 | Common Stock | MOption exerciseAcquired | +2,912 | –F1 | – | 45,390 | Direct | |
| Apr 6, 2023 | Common Stock | SSaleDisposed | −771 | $20.03 | −$15,443.13 | 44,619 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2023 | Common Stock | MOption exerciseDisposed | −2,912 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
Referenced by the price of 1 transaction in Table I.
- F2
The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
- F3
This reflects the total amount beneficially owned by the reporting person as of April 10, 2023. Subsequent Form 4's filed by the reporting person after April 10, 2023 do not currently reflect the vesting of the 2,912 shares.